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Abstract
A 38-year-old female with a 7-year history of recurrent high-grade 
astrocytoma was admitted to our institution presenting with progressive 
signs of increased intracranial pressure. MRI showed widespread 
tumor recurrence with diffuse infiltration of the ventricular walls, basal 
cisterns and concomitant hydrocephalus. After careful consideration 
a palliative endoscopic third ventriculostomy was performed. After 
surgery the patient’s condition improved significantly. Thus far she 
had only undergone radiation, therefore now chemotherapy was 
initiated. After 4 courses of Temozolomide a follow-up MRI showed no 
pathologic contrast enhancement. Six months later the patient is still 
alive in good clinical condition (KPS 90%).
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Case Presentation
Due to intermittent dyslexia with dysphasia and progressive 
headache, an MRI was performed showing an inhomogeneous, 
partially cystic lesion in the left parieto-occipital lobe with surrounding 
edema and space occupying effect. No contrast agent was applied due 
to the patient’s pregnancy (Figure 1). The first surgery for reduction of 
intracranial pressure and histopathological evaluation was performed 
in August 2009 while preserving the pregnancy. Histopathological 
evaluation showed a high-grade astrocytoma without clear-cut 
necrosis and with a Mib-1 proliferation rate of 15%. However 
glioblastoma multiforme was diagnosed, since definite vascular 
proliferations were seen (Figure 2(a, b & d) [3,4]. The standard 
combined radio-chemotherapy [5] was primarily postponed due to 
the patient’s pregnancy, but lateron declined by the patient herself.
In 2011, growth of the residual tumor was noticed with 
inhomogeneous contrast-enhancement and re-operation was 
performed with complete resection (Figure 3). Histopathological 
evaluation showed recurrence of the high-grade astrocytic tumor. 
Standard radio-chemotherapy was recommended again. However, 
based on the patient’s requests only radiation (RT) was performed. 
The former tumor bed region including a peripheral safety margin 
was defined as planning target volume. The patient was treated with 
conformal RT using three non-coplanar wedged 6 MV photon fields. 
The total dose was 60 Gy with 2Gy per fraction. Planar sections of the 
isodose plan are shown in figure 4(a-d).
Follow-up MRI in 2014 showed stable conditions at the primary 
tumor site without signs of recurrence, but a new intraventricular 
manifestation. Complete resection was achieved using an endoscopic 
technique (Figure 5). Histopathological evaluation confirmed 
secondary glioblastoma WHO °IV (IDH-1 positivity, retained nuclear 
ATRX, no loss of 1p19q, MGMT methylated, MIB-1 70%; Figure 2(c, 
Introduction
Despite all therapies, the prognosis of high-grade astrocytomas is 
poor. Adjuvant therapies are known to prolong life, but so far no cure 
is available [1]. Occasionally the clinical course is less aggressive than 
expected and tumors respond surprisingly well to adjuvant treatment, 
which might be due to their histopathologic heterogeneity and their 
specific genetic profile [2].
The median age at diagnosis is 64 for glioblastomas and 45 years 
for anaplastic astrocytomas [1]. Especially the younger patients are 
often in the middle of their lives.
Just like our patient: the 32-year-old woman was 14 weeks 
pregnant when diagnosed with a malignant brain tumor, which 
greatly influences her approach towards treatment. Here we report 
her extraordinary clinical course.
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Figure 1: MRI 2009 (t1 without contrast due to pregnancy). (a-d) preoperative images: cystic, intraaxial lesion in the left pariteo-occipital lobe; postoperative 
images: partial tumor resection; (e-h) postoperative images showing partial tumor resection.
         
Figure 2: Histology of surgical specimen from respective years. (a) 2009: HE-stain - vascular proliferation (#); (b) 2009: HE-stain - atypical mitoses (*); (c) 
2014: GFAP; (d) 2009: MIB 15%; (e) 2014: IDH1; (f) 2014: ATRX; Scale bars for a, c, d, e, f 50 µm, for b 20 µm.
mainly due to hydrocephalus and not tumor progression. Thus, despite 
the highly unfavorable prognosis chemotherapy with temozolomide 
was initiated (160 - 200 mg/m2 BSA, 6 cycles, 5/28). While undergoing 
therapy the patient’s condition further improved. A follow-up MRI 
in September 2015, after 4 cycles of chemotherapy, showed marked 
regression of the tumor without any contrast enhancing tumor remnants 
(Figure 4 (e-h)). Six months after surgery the patient is still alive in good 
clinical condition (KPS 90%).
Discussion
With increasing knowledge about genetic variations within 
astrocytomas, diverging clinical courses despite similar microscopic 
appearance can be explained [1,2,6-8]. This case, despite showing 
histopathological features of a glioblastoma °IV as defined by “The 
2007 WHO Classification of tumors of the central nervous system” 
[3,4] diagnosed at two different pathological institutes, illustrates 
the difficulty with the existing classification. It has become known 
over the past years that molecular profiles might be more relevant 
e & f)). Adjuvant radio-chemotherapy with adapted radiation-volume 
was planned. The treatment planning volume including isodose 
distribution is displayed in figure 4(e-h). A volumetric modulated 
arc therapy (VMAT) with 6 MV photons for dose minimalization in 
the pre-irradiated brain region was applied. Due to side effects, the 
patient refused further treatment after only 3 radiation-sessions (6 
Gy). Concomitant chemotherapy was rejected again.
In May 2015, she was admitted with progressive headache and rapid 
deterioration of her vigilance. MRI revealed severe tumorprogression 
with diffuse infiltration of the ventricular walls and the basal cisterns 
(Figure 6(a-d)) with secondary, occlusive hydrocephalus. After 
thoroughly discussing treatment options and the patient’s wishes with 
the family a palliative endoscopic third ventriculostomy (ETV) was 
performed (Figure 7, Video 1 - supplement). Pathological evaluation of 
the cerebrospinal fluid (CSF), collected during surgery, revealed multiple 
cells of the previously diagnosed glioblastoma, confirming diffuse tumor 
progression. Yet, the patient’s clinical condition improved rapidly after 
surgery, leading to the assumption that her preoperative condition was 
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Figure 3: MRI 2011 (t1 with contrast). (a-d) preoperative images - partially contrast enhancing lesion; (e-h) postoperative images - complete resection.
         
Figure 4: Radiation Target Volume and isodose distribution (axial, coronal). (a, b) post-surgery CT projections (2011); (c, d) corresponding projections in 
the coregistered (fused) preoperative MRI (2011); (e, f) post-surgery CT projections (2015); (g, h) corresponding projections in the coregistered (fused) 
preoperative MRI (2015); (e-f) The bright white line marks the region which has received  ≥ 20 Gy in the first course.
         
Figure 5: MRI 2014 (t1 with contrast). (a-d) preoperative images - secondary intraventricular manifestation without signs of recurrence at the primary site; 
(e-h) postoperative images - complete resection.
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towards prognosis than microscopic patterns [2,7] calling for a new 
classification.
Even though the tumor did presents with a favorable molecular 
profile (secondary malignisation (IDH1 pos), MGMT methylation, 
ATRX retained) [1,8] the effect of chemotherapy was not expected 
         
Figure 6: MRI 2015 (t2 flair with contrast). (a-d) preoperative images - diffuse infiltrative tumor growth with enlarged ventricles; (e-h) images after ETV and 4 
cycles of temozolomide-treatment - tumor regression without pathologic contrast enhancement, normalized ventricular walls.
         
Figure 7: Intraoperative Endoscopic Images. (a, b) Ventricular wall infiltration around Foramen of Monroi; (c) Floor of the 3rd ventricle before perforation; (d) 
Floor of the 3rd ventricle after perforation.
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in this case. Yet, it shows that patients presenting with occlusive 
hydrocephalus and signs of raised intracranial pressure should be 
considered for treatment of the hydrocephalus according to the 
clinic’s standard to allow for a differentiation of symptoms caused 
by hydrocephalus and those caused by tumorprogression itself, 
especially if further adjuvant treatment is still available. In cases of 
occlusive hydrocephalus, ETV poses an elegant option for treatment. 
The patient does not need prolonged external drainage with its 
associated risk of dislocation and infection and no foreign material 
needs to be placed as with a shunt. Furthermore, in cases of shunt 
placement, a high failure rate could be expected due to increased 
protein and cell count in the CSF.
One could argue that extensive therapy in a patient, who refused 
several treatments along the way, is not warranted. But due to the 
disease, her judgment may have been impaired as intracerebral 
tumors are known to cause cognitive deficits, which in turn influences 
treatment decisions [9,10], but may improve over time [11]. When 
being confronted with a life-threatening disease, maintaining quality 
of life is important and thus, some patients may refuse adjuvant 
treatment due to its side effects.
The response witnessed after chemotherapy might partially be 
due to the tumors favorable molecularprofile (MGMT methylated, 
IDH 1 positive) [1,2,8,12], but also due to its temozolomide naivety. 
Furthermore, the widespread infiltration may have lead to a vast 
breakdown ofthe blood-brain barrier, allowing for better penetration 
of the chemotherapeutic agent. This further underlines, if patients 
change their opinion towards treatment during the course of the 
disease and treatment options are still available, even controversial 
measures should be considered.
Conclusion
Patients with malignant brain tumors who present with tumor 
progression and coinciding hydrocephalus should be considered for 
treatment of the hydrocephalus in order to distinguish the causes 
of their deterioration, especially if standard treatment options are 
still available. Furthermore, ETV poses a smart technique for the 
treatment of occlusive hydrocephalus without the need for insertion 
of external drainage or a VP-shunt.
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